MX339201B - Compuestos de sulfonamida y métodos para elaborarlos y usarlos. - Google Patents

Compuestos de sulfonamida y métodos para elaborarlos y usarlos.

Info

Publication number
MX339201B
MX339201B MX2013004079A MX2013004079A MX339201B MX 339201 B MX339201 B MX 339201B MX 2013004079 A MX2013004079 A MX 2013004079A MX 2013004079 A MX2013004079 A MX 2013004079A MX 339201 B MX339201 B MX 339201B
Authority
MX
Mexico
Prior art keywords
methods
compounds
making
same
sulphonamide compounds
Prior art date
Application number
MX2013004079A
Other languages
English (en)
Other versions
MX2013004079A (es
Inventor
Robert Zahler
Hazel Joan Dyke
Thomas David Pallin
Susan Mary Cramp
Original Assignee
Zafgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zafgen Inc filed Critical Zafgen Inc
Publication of MX2013004079A publication Critical patent/MX2013004079A/es
Publication of MX339201B publication Critical patent/MX339201B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/66—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

La invención proporciona compuestos de sulfonamida y su uso en el tratamiento de trastornos médicos, tal como obesidad; se proporcionan composiciones y métodos farmacéuticos para hacer varios compuestos de sulfona; los compuestos se contemplan para tener actividad contra metionil aminopeptidasa 2.
MX2013004079A 2010-10-12 2011-10-12 Compuestos de sulfonamida y métodos para elaborarlos y usarlos. MX339201B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US39210810P 2010-10-12 2010-10-12
US42005010P 2010-12-06 2010-12-06
PCT/US2011/055987 WO2012051318A1 (en) 2010-10-12 2011-10-12 Sulphonamide compounds and methods of making and using same

Publications (2)

Publication Number Publication Date
MX2013004079A MX2013004079A (es) 2013-10-25
MX339201B true MX339201B (es) 2016-05-13

Family

ID=44903376

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013004079A MX339201B (es) 2010-10-12 2011-10-12 Compuestos de sulfonamida y métodos para elaborarlos y usarlos.

Country Status (10)

Country Link
US (1) US9221787B2 (es)
EP (1) EP2627632A1 (es)
JP (1) JP5913333B2 (es)
KR (1) KR20140026330A (es)
CN (1) CN103370307B (es)
AU (1) AU2011316550A1 (es)
BR (1) BR112013008856A2 (es)
CA (1) CA2814413A1 (es)
MX (1) MX339201B (es)
WO (1) WO2012051318A1 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120004162A1 (en) 2008-12-04 2012-01-05 Vath James E Methods of Treating an Overweight or Obese Subject
WO2013055385A2 (en) 2011-10-03 2013-04-18 Zafgen Corporation Methods of treating age related disorders
WO2010065883A2 (en) 2008-12-04 2010-06-10 Zafgen Corporation Method of treating an overweight or obese subject
CA2777108A1 (en) 2009-10-09 2011-04-14 Zafgen Corporation Sulphone compounds and methods of making and using same
US8815309B2 (en) 2010-01-08 2014-08-26 Zafgen, Inc. Methods of treating a subject with benign prostate hyperplasia
BR112012016793A2 (pt) 2010-01-08 2018-07-31 Zafgen Corp compostos tipo fumagilol e métodos de fazer e usar os mesmos
WO2011127304A2 (en) 2010-04-07 2011-10-13 Zafgen Corporation Methods of treating an overweight subject
JP5913310B2 (ja) 2010-07-22 2016-04-27 ザフゲン，インコーポレイテッド 三環式化合物ならびにその作製および使用方法
WO2012075020A1 (en) 2010-11-29 2012-06-07 Zafgen Corporation Treatment of obesity using non-daily administration of 6 - 0 - (4 - dimethylaminoethoxy) cinnamoyl fumagillol
BR112013018771A2 (pt) 2011-01-26 2019-09-17 Zafgen Inc compostos de tetrazol e métodos para fazer e usar os mesmos
WO2012122264A1 (en) 2011-03-08 2012-09-13 Zafgen Corporation Oxaspiro [2.5] octane derivatives and analogs
US9187494B2 (en) 2011-05-06 2015-11-17 Zafgen, Inc. Aryl-substituted tricyclic sulfonamides as methionyl aminopeptidase 2 modulators
CA2835261C (en) 2011-05-06 2019-06-04 Zafgen, Inc. Partially saturated tricyclic compounds and methods of making and using same
MX343688B (es) 2011-05-06 2016-11-16 Zafgen Inc Compuestos tricíclicos de sulfonamida y pirazolo y métodos para su fabricación y uso.
CN104169268A (zh) 2012-01-18 2014-11-26 扎夫根股份有限公司 三环砜化合物及其制备和使用方法
US9359369B2 (en) 2012-01-18 2016-06-07 Zafgen, Inc. Tricyclic sulfonamide compounds and methods of making and using same
WO2013169857A1 (en) 2012-05-08 2013-11-14 Zafgen, Inc. Treating hypothalamic obesity with metap2 inhibitors
JP6177888B2 (ja) 2012-05-09 2017-08-09 ザフゲン，インコーポレイテッド フマギロール型化合物ならびにその製造および使用方法
NZ707773A (en) 2012-11-05 2019-05-31 Zafgen Inc Methods of treating liver diseases
CA2890344A1 (en) 2012-11-05 2014-05-08 Zafgen, Inc. Tricyclic compounds for use in the treatment and/or control of obesity
JP2015536981A (ja) 2012-11-05 2015-12-24 ザフゲン，インコーポレイテッド 三環式化合物ならびにその製造および使用方法
MX362391B (es) 2013-03-14 2019-01-15 Zafgen Inc Métodos de tratamiento de enfermedad renal y otros trastornos.
WO2015184214A1 (en) 2014-05-30 2015-12-03 Dow Corning Corporation Process of synthesizing diisopropylaminw-disilanes
US20170253607A1 (en) * 2014-09-11 2017-09-07 Shionogi & Co., Ltd. Long-acting hiv protease inhibitor
CN106432255A (zh) 2015-08-11 2017-02-22 扎夫根公司 烟曲霉素醇螺环化合物和制备和使用其的方法
AR105671A1 (es) 2015-08-11 2017-10-25 Zafgen Inc Compuestos heterocíclicos de fumagillol y sus métodos de elaboración y uso
IT202100022172A1 (it) * 2021-08-23 2023-02-23 Natural Acad S R L Composizione liquida medicale per somministrazione aerea
WO2023212095A1 (en) * 2022-04-27 2023-11-02 The Regents Of The University Of California Molecules that enhance extracellular vesicle release

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6551611B2 (en) * 1995-09-28 2003-04-22 Schering Aktiengesellschaft Hormone replacement therapy method
US7491718B2 (en) 2002-10-08 2009-02-17 Abbott Laboratories Sulfonamides having antiangiogenic and anticancer activity
DE102007020492A1 (de) * 2007-04-30 2008-11-06 Grünenthal GmbH Substituierte Sulfonamid-Derivate
AU2008282903B2 (en) * 2007-07-30 2011-06-30 Encysive Pharmaceuticals, Inc. Modulators of CCR9 receptor and methods of use thereof
DK2227466T3 (da) 2007-11-30 2011-08-08 Bayer Schering Pharma Ag Heteroaryl-substituerede piperidiner
WO2010065879A2 (en) * 2008-12-04 2010-06-10 Zafgen Corporation Methods of treating an overweight or obese subject
CA2777108A1 (en) 2009-10-09 2011-04-14 Zafgen Corporation Sulphone compounds and methods of making and using same
JP5913310B2 (ja) 2010-07-22 2016-04-27 ザフゲン，インコーポレイテッド 三環式化合物ならびにその作製および使用方法
BR112013018771A2 (pt) 2011-01-26 2019-09-17 Zafgen Inc compostos de tetrazol e métodos para fazer e usar os mesmos
US9187494B2 (en) 2011-05-06 2015-11-17 Zafgen, Inc. Aryl-substituted tricyclic sulfonamides as methionyl aminopeptidase 2 modulators
CA2835261C (en) 2011-05-06 2019-06-04 Zafgen, Inc. Partially saturated tricyclic compounds and methods of making and using same
MX343688B (es) 2011-05-06 2016-11-16 Zafgen Inc Compuestos tricíclicos de sulfonamida y pirazolo y métodos para su fabricación y uso.

Also Published As

Publication number Publication date
JP2013539789A (ja) 2013-10-28
US20130217759A1 (en) 2013-08-22
CA2814413A1 (en) 2012-04-19
CN103370307A (zh) 2013-10-23
MX2013004079A (es) 2013-10-25
EP2627632A1 (en) 2013-08-21
KR20140026330A (ko) 2014-03-05
US9221787B2 (en) 2015-12-29
WO2012051318A1 (en) 2012-04-19
WO2012051318A8 (en) 2013-05-23
JP5913333B2 (ja) 2016-04-27
CN103370307B (zh) 2016-05-25
AU2011316550A1 (en) 2013-05-02
BR112013008856A2 (pt) 2016-06-21

Similar Documents

Publication Publication Date Title
MX339201B (es) Compuestos de sulfonamida y métodos para elaborarlos y usarlos.
MX343687B (es) Compuestos sulfonamida tricíclica y métodos para su fabricación y uso.
MX343688B (es) Compuestos tricíclicos de sulfonamida y pirazolo y métodos para su fabricación y uso.
MX344238B (es) Compuestos de tetrazol y métodos para preparar y usar los mismos.
MX2014008706A (es) Compuestos tricíclicos de sulfonamida y métodos para elaborarlos y usarlos.
MX2014008705A (es) Compuestos tricíclicos de sulfona y métodos para elaborarlos y utilizarlos.
AU2012253757A8 (en) Partially saturated tricyclic compounds and methods of making and using same
WO2011044506A3 (en) Sulphone compounds for use in the treatment of obesity
MX343135B (es) Compuestos de tipo fumagilol y métodos de realización y uso de los mismos.
BR112013001613A2 (pt) compostos tricíclicos e métodos para fazer e usar os mesmos.
PH12013500145B1 (en) Agonists of gpr40
PH12016500105A1 (en) Sulfonamides as modulators of sodium channels
UA105290C2 (ru) АПТАМЕРЫ К β-NGF И ИХ ПРИМЕНЕНИЕ ПРИ ЛЕЧЕНИИ β-NGF-ОПОСРЕДОВАННЫХ ЗАБОЛЕВАНИЙ И РАССТРОЙСТВ
PH12013500467A1 (en) Pharmaceutical composition
MX356755B (es) Compuestos de tipo fumagilol y metodos para su elaboración y uso.
EA201300471A1 (ru) Замещенные 6-аминоникотинамиды в качестве модуляторов kcnq2/3
PH12018500315A1 (en) Fumagillol heterocyclic compounds and methods of making and using same
MX342947B (es) Tratamiento de diabetes tipo 2.
PH12012501389A1 (en) Hedgehog inhibitors
MX2015005732A (es) Compuestos tricíclicos y métodos para hacer y utilizar los mismos.
PH12014502623A1 (en) Difluoro-hexahydro-cyclopentaoxazinyls and difluoro-hexahydro-benzooxazinyls as bace1 inhibitors
MX342119B (es) 2-oxi-quinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3.
MX2013002121A (es) Quinolina-3-carboxamidas sustituidas como moduladores de kcnq2/3.
MX2015005733A (es) Compuestos triciclicos para usarse en el tratamiento y/o control de obesidad.
CY1116158T1 (el) Υποκατεστημενα 2-οξο- και 2-θειοξο-διυδροκινολινο-3-καρβοξαμιδια σαν διαμορφωτες kcnq2/3

Legal Events

Date Code Title Description
FG Grant or registration